

A Novel Anti-DR5 Antibody-Drug Conjugate

Drug Name	***0156
Description	Death receptor 5 (DR5), also known as TRAIL receptor 2 (TRAILR2) is a cell surface receptor that binds TRAIL and mediates apoptosis. An antibody-drug conjugate consisting of an antibody targeting DR5 linked to monomethyl dolastatin 10 (MMAD, a tubulin inhibitor) is in preclinical development. These preclinical data demonstrate that the product is a potential cancer therapeutic agent.
Target	DR5; Tubulin
Drug Modality	Antibody-Drug Conjugate
Indication	Cancer
Product Category	Apoptosis Inducer
Mechanism of Action	Targeting DR5 and inducing apoptosis of tumor cells
Status	Preclinical
Patent	Granted

More Detail Available Upon Request

We look forward to hearing from you.